Literature DB >> 16816976

[Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].

M Goepel1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16816976     DOI： 10.1007/s00120-006-1121-8

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  7 in total

1.  Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70.

Authors:  Udo Jonas; Raymond R Rackley
Journal:  Eur Urol       Date:  2005-11-15       Impact factor: 20.096

2.  A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial.

Authors:  C R Chapple; R Martinez-Garcia; L Selvaggi; P Toozs-Hobson; W Warnack; T Drogendijk; D M Wright; J Bolodeoku
Journal:  Eur Urol       Date:  2005-09       Impact factor: 20.096

3.  A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT).

Authors:  Paul Siami; Larry S Seidman; Daniel Lama
Journal:  Clin Ther       Date:  2002-04       Impact factor: 3.393

4.  Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.

Authors:  Ananias C Diokno; Rodney A Appell; Peter K Sand; Roger R Dmochowski; Bernard M Gburek; Ira W Klimberg; Sherron H Kell
Journal:  Mayo Clin Proc       Date:  2003-06       Impact factor: 7.616

5.  Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.

Authors:  C R Chapple; T Rechberger; S Al-Shukri; P Meffan; K Everaert; M Huang; A Ridder
Journal:  BJU Int       Date:  2004-02       Impact factor: 5.588

6.  Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.

Authors:  Vik Khullar; Simon Hill; Karl-Ulrich Laval; Hjalmar A Schiøtz; Udo Jonas; Eboo Versi
Journal:  Urology       Date:  2004-08       Impact factor: 2.649

7.  Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder.

Authors:  L Cardozo; M Lisec; R Millard; O van Vierssen Trip; I Kuzmin; T E Drogendijk; M Huang; A M Ridder
Journal:  J Urol       Date:  2004-11       Impact factor: 7.450
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.